US Patent Issued to AFFILIATED HOSPITAL OF JIANGNAN UNIVERSITY on July 1 for "Ligand-targeted cell conjugate (LTCC)-based anti-tumor immune cell" (Chinese Inventors)

ALEXANDRIA, Va., July 3 -- United States Patent no. 12,343,404, issued on July 1, was assigned to AFFILIATED HOSPITAL OF JIANGNAN UNIVERSITY (Jiangsu, China).

"Ligand-targeted cell conjugate (LTCC)-based anti-tumor immune cell" was invented by Zhaohui Huang (Jiangsu, China), Zhimeng Wu (Jiangsu, China), Liang Gong (Jiangsu, China) and Yanchun Li (Jiangsu, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "Non-natural sugars modified with a bioorthogonal reactive group are added into a culture medium of immune cells such as NK cells to obtain immune cells modified with the bioorthogonal reactive group; and then, under a physiological condition, a targeting ligand, for example, a nanobody, is modified to a s...